Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Naratriptan Hydrochloride

FDA-approved product (tablet, oral), marketed as Amerge, Naratriptan.

Registered studies
4
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Naratriptan Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Migraine disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Selective serotonin (5ht1) agonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli47.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae35.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

4registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Naratriptan Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Naratriptan Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet

    NCT01376193 · start 2009-04

    Registered record
    Registry ID
    NCT01376193
    Conditions
    Migraine Disorders
    Interventions
    Naratriptan
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-04
    Completion
    2011-10
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Disorders
    InterventionNaratriptan
    PhaseNot recorded
    Registry statusCompleted

  • Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fasted Conditions

    NCT01161667 · start 2007-09

    Registered record
    Registry ID
    NCT01161667
    Conditions
    Migraine
    Interventions
    naratriptan hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-09
    Completion
    2007-09
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    Interventionnaratriptan hydrochloride
    PhaseNot applicable
    Registry statusCompleted

  • Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fed Conditions

    NCT01161654 · start 2007-08

    Registered record
    Registry ID
    NCT01161654
    Conditions
    Migraine
    Interventions
    naratriptan hydrochoride
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-08
    Completion
    2007-09
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    Interventionnaratriptan hydrochoride
    PhaseNot applicable
    Registry statusCompleted

  • Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction

    NCT00487578 · start 2006-10

    Registered record
    Registry ID
    NCT00487578
    Conditions
    Post Traumatic Headache
    Interventions
    naratriptan HCl
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2006-10
    Completion
    2009-10
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost Traumatic Headache
    Interventionnaratriptan HCl
    PhasePhase 4
    Registry statusTerminated